ArticleJournal of pharmacology & pharmacotherapeutics
Suvorexant: The first orexin receptor antagonist to treat insomnia.
Article in Journal of pharmacology & pharmacotherapeutics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant.Frontiers in psychiatry · 2022Pooled it
- Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.PloS one · 2015Pooled it
- Effect of suvorexant on nighttime blood pressure in hypertensive patients with insomnia: The SUPER-1 study.Journal of clinical hypertension (Greenwich, Conn.) · 2019Trial
- Central hypocretin/orexin administration alleviates sleep/wake disturbances, anhedonia, and neuroinflammation in an animal model of seasonal affective disorder.Annals of medicine · 2026Article
- Unlocking the Power of Plant-Derived Natural Products: Therapeutic Benefits for Cognitive Health and Neuropsychiatric Symptoms in Dementia-Related Diseases.Plants (Basel, Switzerland) · 2026Review
- Efficacy and Safety Profile of Suvorexant for the Treatment of Insomnia.Current drug safety · 2026Review
- Total Alkaloid Extract of Nelumbinis Plumula Promoted Sleep in PCPA-Induced Insomnia Rats by Affecting Neurotransmitters and Their Receptor Activities.International journal of molecular sciences · 2025Article
- Synthesis and Optical Properties ofMolecules (Basel, Switzerland) · 2025Article
- Dual orexin receptor antagonists as promising therapeutics for Alzheimer's disease.Npj biological timing and sleep · 2025Review
- A Pharmacological Update of Oxadiazole Derivatives: A Review.Current topics in medicinal chemistry · 2025Review
- A male-specific mechanism of meningeal nociceptor sensitization promoting migraine headache.Cephalalgia : an international journal of headache · 2024Article
- Periostracum Cicadae Extract and N-Acetyldopamine Regulate the Sleep-Related Neurotransmitters in PCPA-Induced Insomnia Rats.Molecules (Basel, Switzerland) · 2024Article
- The Role of Orexin Receptor Antagonists in Inhibiting Drug Addiction: A Review Article.Addiction & health · 2024Review
- Quantification of Suvorexant in Human Urine Using a Validated HPTLC Bioanalytical Method.ACS omega · 2023Article
- 2023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults - Brazilian Sleep Association.Sleep science (Sao Paulo, Brazil) · 2023Review
- Clinical Spectrum and Trajectory of Innovative Therapeutic Interventions for Insomnia: A Perspective.Aging and disease · 2023Article
- A study on the effect of JNJ-10397049 on proliferation and differentiation of neural precursor cells.Anatomy & cell biology · 2022Article
- Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia.Health psychology research · 2022Article
- Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation.Nature communications · 2021Article
- Antinociceptive effects of oleuropein in experimental models of neuropathic pain in male rats.The Korean journal of pain · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary insomnia is mainly treated with drugs acting on benzodiazepine receptors and a few other classes of drugs used for different co-morbidities. A novel approach to treat insomnia has been introduced recently, with the approval of suvorexant, the first in a new class of orexin receptor antagonists. Orexin receptors in the brain have been found to play an important role in the regulation of various aspects of arousal and motivation. The drugs commonly used for insomnia therapy to date, have often been associated with adverse effects, such as, day-time somnolence, amnesia, confusion, and gait disturbance, apart from the risk of dependence on chronic use. Suvorexant has not shown these adverse effects because of its unique mechanism of action. It also appears to be suitable as a chronic therapy for insomnia, because of minimal physical dependence. The availability of this new drug as an effective and safe alternative is an important and welcome development in insomnia management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.